{"id":13021,"date":"2020-03-25T05:42:00","date_gmt":"2020-03-25T10:42:00","guid":{"rendered":"https:\/\/en.ennov.com\/?p=13021"},"modified":"2022-05-23T02:33:23","modified_gmt":"2022-05-23T07:33:23","slug":"fda-guidance-post-marketing-adverse-event-reporting","status":"publish","type":"post","link":"https:\/\/dqdev.co\/ennov\/blog\/pharmacovigilance-blog\/fda-guidance-post-marketing-adverse-event-reporting\/","title":{"rendered":"FDA Guidance on Post-marketing Adverse Event Reporting During a Pandemic"},"content":{"rendered":"\n<p>The&nbsp;<strong>FDA<\/strong> has issued a formal <strong>guidance document<\/strong> providing recommendations to industry regarding <strong>post-marketing adverse event reporting <\/strong>for drugs, biologics, medical devices, combination products, and dietary supplements <strong>during a pandemic<\/strong>.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\"><p><em>FDA anticipates that during a pandemic, industry and FDA workforces may be reduced because of high employee absenteeism while reporting of adverse events related to the widespread use of medical products indicated for the treatment or prevention of the pathogen causing the pandemic may increase. The extent of these possible changes is unknown.<\/em><\/p><\/blockquote>\n\n\n\n<p>Some <strong>key points from the guidance<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>Even during a pandemic, <strong>firms should continue to handle adverse event data<\/strong> per existing standard operating procedures and regulatory and statutory requirements, as much as possible.<\/li><li>Firms should have in place a <strong>Continuity of Operations Plan (COOP)<\/strong> to ensure that a firm\u2019s operations continue during all stages of a pandemic, including instructions for reporting adverse events as well as a plan for the submission of any stored reports not submitted in the regulatory timeframes.<\/li><li>Firms that are unable to fulfill normal adverse event reporting requirements during a pandemic should maintain documentation of both of the following conditions:<ul><li>Declaration of a pandemic (e.g., by the World Health Organization), including date of declaration of the pandemic and ending date of the pandemic<\/li><li>High absenteeism and\/or other factors (e.g., an increase in adverse event reporting) that is\/are preventing the firm from meeting normal adverse event reporting requirements<\/li><\/ul><\/li><li>Following the resolution of the pandemic, firms should resume fulfilling all normal, pre-pandemic requirements, including the submission of any stored reports not submitted during standard regulatory timeframes during the pandemic.<\/li><\/ul>\n\n\n\n<p>Read the&nbsp;<a href=\"https:\/\/www.fda.gov\/media\/72498\/download\" target=\"_blank\" rel=\"noreferrer noopener\">full guidance<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The&nbsp;FDA has issued a formal guidance document providing recommendations to industry regarding post-marketing adverse event reporting for drugs, biologics, medical devices, combination products, and dietary supplements during a pandemic. FDA anticipates that during a pandemic, industry and FDA workforces may be reduced because of high employee absenteeism while reporting of adverse events related to the [&hellip;]<\/p>\n","protected":false},"author":232,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"content-type":"","footnotes":""},"categories":[146],"tags":[],"type_content":[],"job":[],"employees_type":[],"class_list":["post-13021","post","type-post","status-publish","format-standard","hentry","category-pharmacovigilance-blog","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v19.2.1 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>FDA Guidance: Post-marketing Adverse Event Reporting during Pandemic<\/title>\n<meta name=\"description\" content=\"Post-marketing adverse event reporting for drugs, biologics, medical devices, and dietary supplements during a pandemic.\" \/>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA Guidance on Post-marketing Adverse Event Reporting During a Pandemic\" \/>\n<meta property=\"og:description\" content=\"Post-marketing adverse event reporting for drugs, biologics, medical devices, and dietary supplements during a pandemic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/dqdev.co\/ennov\/blog\/pharmacovigilance-blog\/fda-guidance-post-marketing-adverse-event-reporting\/\" \/>\n<meta property=\"og:site_name\" content=\"Ennov Software for Life\" \/>\n<meta property=\"article:published_time\" content=\"2020-03-25T10:42:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-05-23T07:33:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/dqdev.co\/ennov\/wp-content\/uploads\/2022\/09\/Ennov-Software-for-Life-Hiring.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"627\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Alex Chappell\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@EnnovGroup\" \/>\n<meta name=\"twitter:site\" content=\"@EnnovGroup\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Alex Chappell\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/dqdev.co\\\/ennov\\\/blog\\\/pharmacovigilance-blog\\\/fda-guidance-post-marketing-adverse-event-reporting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/dqdev.co\\\/ennov\\\/blog\\\/pharmacovigilance-blog\\\/fda-guidance-post-marketing-adverse-event-reporting\\\/\"},\"author\":{\"name\":\"Alex Chappell\",\"@id\":\"https:\\\/\\\/dqdev.co\\\/ennov\\\/#\\\/schema\\\/person\\\/ebc4deb7c360f7a979b3af96c6150941\"},\"headline\":\"FDA Guidance on Post-marketing Adverse Event Reporting During a Pandemic\",\"datePublished\":\"2020-03-25T10:42:00+00:00\",\"dateModified\":\"2022-05-23T07:33:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/dqdev.co\\\/ennov\\\/blog\\\/pharmacovigilance-blog\\\/fda-guidance-post-marketing-adverse-event-reporting\\\/\"},\"wordCount\":284,\"publisher\":{\"@id\":\"https:\\\/\\\/dqdev.co\\\/ennov\\\/#organization\"},\"articleSection\":[\"Pharmacovigilance - Blog\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/dqdev.co\\\/ennov\\\/blog\\\/pharmacovigilance-blog\\\/fda-guidance-post-marketing-adverse-event-reporting\\\/\",\"url\":\"https:\\\/\\\/dqdev.co\\\/ennov\\\/blog\\\/pharmacovigilance-blog\\\/fda-guidance-post-marketing-adverse-event-reporting\\\/\",\"name\":\"FDA Guidance: Post-marketing Adverse Event Reporting during Pandemic\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/dqdev.co\\\/ennov\\\/#website\"},\"datePublished\":\"2020-03-25T10:42:00+00:00\",\"dateModified\":\"2022-05-23T07:33:23+00:00\",\"description\":\"Post-marketing adverse event reporting for drugs, biologics, medical devices, and dietary supplements during a pandemic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/dqdev.co\\\/ennov\\\/blog\\\/pharmacovigilance-blog\\\/fda-guidance-post-marketing-adverse-event-reporting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/dqdev.co\\\/ennov\\\/blog\\\/pharmacovigilance-blog\\\/fda-guidance-post-marketing-adverse-event-reporting\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/dqdev.co\\\/ennov\\\/blog\\\/pharmacovigilance-blog\\\/fda-guidance-post-marketing-adverse-event-reporting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/dqdev.co\\\/ennov\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FDA Guidance on Post-marketing Adverse Event Reporting During a Pandemic\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/dqdev.co\\\/ennov\\\/#website\",\"url\":\"https:\\\/\\\/dqdev.co\\\/ennov\\\/\",\"name\":\"Ennov Software for Life\",\"description\":\"Unified Content Management Platform Software for Life Sciences\",\"publisher\":{\"@id\":\"https:\\\/\\\/dqdev.co\\\/ennov\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/dqdev.co\\\/ennov\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/dqdev.co\\\/ennov\\\/#organization\",\"name\":\"Ennov\",\"url\":\"https:\\\/\\\/dqdev.co\\\/ennov\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/dqdev.co\\\/ennov\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/en.ennov.com\\\/wp-content\\\/uploads\\\/2019\\\/02\\\/ennov-social-graph-1.jpg\",\"contentUrl\":\"https:\\\/\\\/en.ennov.com\\\/wp-content\\\/uploads\\\/2019\\\/02\\\/ennov-social-graph-1.jpg\",\"width\":672,\"height\":672,\"caption\":\"Ennov\"},\"image\":{\"@id\":\"https:\\\/\\\/dqdev.co\\\/ennov\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/EnnovGroup\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/81570\\\/admin\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/dqdev.co\\\/ennov\\\/#\\\/schema\\\/person\\\/ebc4deb7c360f7a979b3af96c6150941\",\"name\":\"Alex Chappell\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/dqdev.co\\\/ennov\\\/wp-content\\\/uploads\\\/2022\\\/02\\\/ennov-e.png\",\"url\":\"https:\\\/\\\/dqdev.co\\\/ennov\\\/wp-content\\\/uploads\\\/2022\\\/02\\\/ennov-e.png\",\"contentUrl\":\"https:\\\/\\\/dqdev.co\\\/ennov\\\/wp-content\\\/uploads\\\/2022\\\/02\\\/ennov-e.png\",\"caption\":\"Alex Chappell\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"FDA Guidance: Post-marketing Adverse Event Reporting during Pandemic","description":"Post-marketing adverse event reporting for drugs, biologics, medical devices, and dietary supplements during a pandemic.","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"FDA Guidance on Post-marketing Adverse Event Reporting During a Pandemic","og_description":"Post-marketing adverse event reporting for drugs, biologics, medical devices, and dietary supplements during a pandemic.","og_url":"https:\/\/dqdev.co\/ennov\/blog\/pharmacovigilance-blog\/fda-guidance-post-marketing-adverse-event-reporting\/","og_site_name":"Ennov Software for Life","article_published_time":"2020-03-25T10:42:00+00:00","article_modified_time":"2022-05-23T07:33:23+00:00","og_image":[{"width":1200,"height":627,"url":"https:\/\/dqdev.co\/ennov\/wp-content\/uploads\/2022\/09\/Ennov-Software-for-Life-Hiring.png","type":"image\/png"}],"author":"Alex Chappell","twitter_card":"summary_large_image","twitter_creator":"@EnnovGroup","twitter_site":"@EnnovGroup","twitter_misc":{"Written by":"Alex Chappell","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/dqdev.co\/ennov\/blog\/pharmacovigilance-blog\/fda-guidance-post-marketing-adverse-event-reporting\/#article","isPartOf":{"@id":"https:\/\/dqdev.co\/ennov\/blog\/pharmacovigilance-blog\/fda-guidance-post-marketing-adverse-event-reporting\/"},"author":{"name":"Alex Chappell","@id":"https:\/\/dqdev.co\/ennov\/#\/schema\/person\/ebc4deb7c360f7a979b3af96c6150941"},"headline":"FDA Guidance on Post-marketing Adverse Event Reporting During a Pandemic","datePublished":"2020-03-25T10:42:00+00:00","dateModified":"2022-05-23T07:33:23+00:00","mainEntityOfPage":{"@id":"https:\/\/dqdev.co\/ennov\/blog\/pharmacovigilance-blog\/fda-guidance-post-marketing-adverse-event-reporting\/"},"wordCount":284,"publisher":{"@id":"https:\/\/dqdev.co\/ennov\/#organization"},"articleSection":["Pharmacovigilance - Blog"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/dqdev.co\/ennov\/blog\/pharmacovigilance-blog\/fda-guidance-post-marketing-adverse-event-reporting\/","url":"https:\/\/dqdev.co\/ennov\/blog\/pharmacovigilance-blog\/fda-guidance-post-marketing-adverse-event-reporting\/","name":"FDA Guidance: Post-marketing Adverse Event Reporting during Pandemic","isPartOf":{"@id":"https:\/\/dqdev.co\/ennov\/#website"},"datePublished":"2020-03-25T10:42:00+00:00","dateModified":"2022-05-23T07:33:23+00:00","description":"Post-marketing adverse event reporting for drugs, biologics, medical devices, and dietary supplements during a pandemic.","breadcrumb":{"@id":"https:\/\/dqdev.co\/ennov\/blog\/pharmacovigilance-blog\/fda-guidance-post-marketing-adverse-event-reporting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/dqdev.co\/ennov\/blog\/pharmacovigilance-blog\/fda-guidance-post-marketing-adverse-event-reporting\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/dqdev.co\/ennov\/blog\/pharmacovigilance-blog\/fda-guidance-post-marketing-adverse-event-reporting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/dqdev.co\/ennov\/"},{"@type":"ListItem","position":2,"name":"FDA Guidance on Post-marketing Adverse Event Reporting During a Pandemic"}]},{"@type":"WebSite","@id":"https:\/\/dqdev.co\/ennov\/#website","url":"https:\/\/dqdev.co\/ennov\/","name":"Ennov Software for Life","description":"Unified Content Management Platform Software for Life Sciences","publisher":{"@id":"https:\/\/dqdev.co\/ennov\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/dqdev.co\/ennov\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/dqdev.co\/ennov\/#organization","name":"Ennov","url":"https:\/\/dqdev.co\/ennov\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/dqdev.co\/ennov\/#\/schema\/logo\/image\/","url":"https:\/\/en.ennov.com\/wp-content\/uploads\/2019\/02\/ennov-social-graph-1.jpg","contentUrl":"https:\/\/en.ennov.com\/wp-content\/uploads\/2019\/02\/ennov-social-graph-1.jpg","width":672,"height":672,"caption":"Ennov"},"image":{"@id":"https:\/\/dqdev.co\/ennov\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/EnnovGroup","https:\/\/www.linkedin.com\/company\/81570\/admin\/"]},{"@type":"Person","@id":"https:\/\/dqdev.co\/ennov\/#\/schema\/person\/ebc4deb7c360f7a979b3af96c6150941","name":"Alex Chappell","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/dqdev.co\/ennov\/wp-content\/uploads\/2022\/02\/ennov-e.png","url":"https:\/\/dqdev.co\/ennov\/wp-content\/uploads\/2022\/02\/ennov-e.png","contentUrl":"https:\/\/dqdev.co\/ennov\/wp-content\/uploads\/2022\/02\/ennov-e.png","caption":"Alex Chappell"}}]}},"_links":{"self":[{"href":"https:\/\/dqdev.co\/ennov\/wp-json\/wp\/v2\/posts\/13021","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dqdev.co\/ennov\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dqdev.co\/ennov\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dqdev.co\/ennov\/wp-json\/wp\/v2\/users\/232"}],"replies":[{"embeddable":true,"href":"https:\/\/dqdev.co\/ennov\/wp-json\/wp\/v2\/comments?post=13021"}],"version-history":[{"count":0,"href":"https:\/\/dqdev.co\/ennov\/wp-json\/wp\/v2\/posts\/13021\/revisions"}],"wp:attachment":[{"href":"https:\/\/dqdev.co\/ennov\/wp-json\/wp\/v2\/media?parent=13021"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dqdev.co\/ennov\/wp-json\/wp\/v2\/categories?post=13021"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dqdev.co\/ennov\/wp-json\/wp\/v2\/tags?post=13021"},{"taxonomy":"type_content","embeddable":true,"href":"https:\/\/dqdev.co\/ennov\/wp-json\/wp\/v2\/type_content?post=13021"},{"taxonomy":"job","embeddable":true,"href":"https:\/\/dqdev.co\/ennov\/wp-json\/wp\/v2\/job?post=13021"},{"taxonomy":"employees_type","embeddable":true,"href":"https:\/\/dqdev.co\/ennov\/wp-json\/wp\/v2\/employees_type?post=13021"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}